After intravenous administration in tumor-bearing mice, CHA-rGO/Dox displayed higher tumor accumulation than rGO/Dox facilitating the cellular uptake of Dox by CD44-overexpressing tumor cells with enhanced anticancer effects. This evidence concerns the gene CD44 and neoplasm.